Xenetic Biosciences, Inc. Appoints Jeffrey F. Eisenberg as Chief Operating Officer
December 05, 2016 at 07:05 am EST
Share
Xenetic Biosciences, Inc. announced it has appointed Jeffrey F. Eisenberg as Chief Operating Officer. Mr. Eisenberg is a life science executive with over 20 years of operational experience who has been serving on Xenetic’s Board of Directors since July 2016. Over the course of his career, Mr. Eisenberg has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management. Prior to joining the Xenetic management team, Mr. Eisenberg has served on the Company’s Board of Directors since July 2016. Previously, he served at Noven Pharmaceuticals, Inc. for over a decade beginning as Vice President, General Counsel and Corporate Secretary and departing as the President and CEO and a member of the Board of Directors.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
XENETIC BIOSCIENCES, INC. 
